| |
|
| Source: Company documents |
|
|
| Name
: |
John P. Richard |
| Title
: |
Chairman of the Board |
| Since: |
10/2004 |
|
|
|
|
| Name
: |
Phil Gotwals |
| Title
: |
Vice President, Program Management |
| Since: |
01/2008 |
|
|
|
| Name
: |
Jonathan I. Lieber |
| Title
: |
Chief Financial Officer, Vice President, Treasurer |
| Since: |
07/2002 |
|
|
|
| Name
: |
Bruce A. Leicher |
| Title
: |
Senior Vice President, General Counsel, Secretary |
| Since: |
12/19/2006 |
|
|
|
| Name
: |
Burkhard Blank |
| Title
: |
Executive Vice President and Chief Medical Officer |
| Since: |
01/2008 |
|
|
|
|
| Name
: |
David D. Pendergast |
| Title
: |
Executive Chairman of the Board |
| Since: |
02/2008 |
|
|
|
| Name
: |
Robert Gallotto |
| Title
: |
Vice President - Strategic Planning and Alliance Management |
| Since: |
2003 |
|
|
|
| Name
: |
Lauren M. Sabella |
| Title
: |
Vice President - Commercial Development |
| Since: |
05/01/2006 |
|
|
|
| Name
: |
John M. Sorvillo |
| Title
: |
Vice President - Business Development |
| Since: |
08/11/2006 |
|
|
|
|
|
|
|
| |
|
| Earnings
Release Dates : 7th May 2008 , 11th March 2008 , 8th August 2007 |
|
 Audio |
|
|
| |
|
| |
|
| |
|
| |
| Chipotle Gains 100% in IPO Jan 30, 5:00 PM EST |
|
| |
Altus Pharmaceuticals, Inc.
The Company has designed Product Candidates ALTU-135 to withstand degradation, maintain its activity across the different pH levels in the gastrointestinal tract, and exert its therapeutic effect in the first part of the small intestine, or the duodenum, where most fats, proteins and carbohydrates are broken down and absorbed.
The Company has designed ALTU-135 to exhibit consistent enzyme activity from batch to batch.
|
| More... |
|
|
|
|
|
